Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Sunitinib × 1 year × Clear all

Sponsor

Conditions

Carcinoma, Renal Cell 16 Gastrointestinal Stromal Tumors 7 Neoplasms 4 Multiple Myeloma 3 Kidney Neoplasms 3 Urologic Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Meningioma 2 Lymphoma, Non-Hodgkin 2 Kidney Diseases 2 Gastrointestinal Neoplasms 2 Carcinoma 2 Adenoma, Islet Cell 2 Uveal Melanoma 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thymoma 1 Thoracic Neoplasms 1 Somatostatinoma 1 Solid Tumors Refractory to Standard Therapy 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Prostatic Neoplasms 1 Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1 Pelvic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Nervous System Neoplasms 1

Interventions

Nivolumab 6 Ipilimumab 5 Cisplatin 5 atezolizumab 4 Carboplatin 4 Etoposide 3 gallium Ga 68 dotatate 2 dostarlimab 2 Temozolomide 2 Positron Emission Tomography Computed Tomography 2 Paclitaxel 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 Drug Therapy 2 Disulfides 2 zimberelimab 1 tivozanib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 niraparib 1 lutetium Lu 177 dotatate 1 iadademstat 1 durvalumab 1 cabozantinib 1 budigalimab 1 berzosertib 1 belinostat 1 Topotecan 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡